ES2124889T3 - Composicion distribuidora de farmacos para agentes bloqueadores alfa-adreno receptores. - Google Patents

Composicion distribuidora de farmacos para agentes bloqueadores alfa-adreno receptores.

Info

Publication number
ES2124889T3
ES2124889T3 ES94916318T ES94916318T ES2124889T3 ES 2124889 T3 ES2124889 T3 ES 2124889T3 ES 94916318 T ES94916318 T ES 94916318T ES 94916318 T ES94916318 T ES 94916318T ES 2124889 T3 ES2124889 T3 ES 2124889T3
Authority
ES
Spain
Prior art keywords
drug
release
composition
adrene
receivers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916318T
Other languages
English (en)
Inventor
Lisbeth Illum
Peter Watts
Nidal Farraj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Application granted granted Critical
Publication of ES2124889T3 publication Critical patent/ES2124889T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EN LA INVENCION SE PRESENTA UNA COMPOSICION PARA EL SUMINISTRO ORAL DE FARMACOS QUE CONTIENE UN FARMACO DE BLOQUEO DE UN RECEPTOR DE {AL}-ADRENO QUE SE CARACTERIZA PORQUE LA COMPOSICION SE ENCUENTRA ADAPTADA PARA QUE LIBERE UNA PRIMERA PORCION DEL FARMACO EN LA PARTE SUPERIOR DEL APARATO GASTROINTESTINAL Y PARA QUE LIBERE UNA SEGUNDA PORCION DEL FARMACO MEDIANTE UNA LIBERACION PROLONGADA EN EL ILEON TERMINAL Y/O EL COLON. ESTA COMPOSICION PRESENTA UN PERFIL DE LIBERACION BIFASICO QUE MANTIENE UNOS NIVELES DE PLASMA SUFICIENTES Y ESTABLES PARA UN EFECTO TERAPEUTICO AL TIEMPO QUE SE MINIMIZAN LOS EFECTOS SECUNDARIOS AL EVITAR QUE HAY UNOS NIVELES DE PLASMA MAXIMOS ALTOS. LA LIBERACION PROLONGADA DE LA SEGUNDA Y OPCIONALMENTE DE LA PRIMERA PORCION DEL FARMACO SE CONSIGUE MEDIANTE UN SISTEMA DE LIBERACION CONTROLADA TAL COMO UNA MATRIZ DE GEL HIDROFILICA. LA LIBERACION ESPECIFICA DE LA SEGUNDA PORCION DEL FARMACO EN EL COLON SE PUEDE CONSEGUIR REVISTIENDO LAS PASTILLAS QUE CONTIENEN LA SEGUNDAPORCION CON UN REVESTIMIENTO SENSIBLE AL PH Y A LA REDUCCION-OXIDACION TAL COMO UN POLIMETILMETACRILATO.
ES94916318T 1993-05-29 1994-05-27 Composicion distribuidora de farmacos para agentes bloqueadores alfa-adreno receptores. Expired - Lifetime ES2124889T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939311191A GB9311191D0 (en) 1993-05-29 1993-05-29 Controlled release drug formulation

Publications (1)

Publication Number Publication Date
ES2124889T3 true ES2124889T3 (es) 1999-02-16

Family

ID=10736382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916318T Expired - Lifetime ES2124889T3 (es) 1993-05-29 1994-05-27 Composicion distribuidora de farmacos para agentes bloqueadores alfa-adreno receptores.

Country Status (12)

Country Link
EP (1) EP0700285B1 (es)
JP (1) JPH09504779A (es)
AT (1) ATE171370T1 (es)
AU (1) AU684786B2 (es)
CA (1) CA2163340A1 (es)
DE (1) DE69413534T2 (es)
DK (1) DK0700285T3 (es)
ES (1) ES2124889T3 (es)
FI (1) FI955730A (es)
GB (2) GB9311191D0 (es)
NO (1) NO306759B1 (es)
WO (1) WO1994027582A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
US6149940A (en) * 1996-08-29 2000-11-21 Synthelabo Tablet with controlled release of alfuzosine chlorhydrate
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
EP1366761A4 (en) * 2001-02-13 2004-04-21 Taisho Pharmaceutical Co Ltd GEL PREPARATIONS FOR INTERNAL USE
BR0315569A (pt) * 2002-10-22 2005-08-30 Ranbaxy Lab Ltd Apresentação farmacêutica de liberação prolongada contendo alfuzosina
WO2007080509A2 (en) 2006-01-12 2007-07-19 Wockhardt Ltd Sustained release compositions of alfuzosin
US20070292505A1 (en) * 2006-06-15 2007-12-20 Abrika Pharmaceuticals, Inc. Controlled release alfuzosin hydrochloride formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1101649B (it) * 1978-12-15 1985-10-07 Lehner Ag Composizione farmaceutica ad azione prolungata contenente acidi biliari
FR2477015A1 (fr) * 1980-03-03 1981-09-04 Fabre Sa Pierre Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung

Also Published As

Publication number Publication date
GB9523191D0 (en) 1996-01-17
DK0700285T3 (da) 1999-02-15
EP0700285B1 (en) 1998-09-23
GB2292315A (en) 1996-02-21
JPH09504779A (ja) 1997-05-13
NO306759B1 (no) 1999-12-20
EP0700285A1 (en) 1996-03-13
GB9311191D0 (en) 1993-07-14
DE69413534T2 (de) 1999-03-18
FI955730A (fi) 1996-01-26
GB2292315B (en) 1997-04-02
ATE171370T1 (de) 1998-10-15
CA2163340A1 (en) 1994-12-08
WO1994027582A1 (en) 1994-12-08
DE69413534D1 (de) 1998-10-29
AU684786B2 (en) 1998-01-08
NO954583D0 (no) 1995-11-14
AU6802094A (en) 1994-12-20
FI955730A0 (fi) 1995-11-28
NO954583L (no) 1995-11-14

Similar Documents

Publication Publication Date Title
PT984774E (pt) Microesferas de libertacao controlada, com retencao gastrica, para uma administracao de drogas melhorada
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
ES2124889T3 (es) Composicion distribuidora de farmacos para agentes bloqueadores alfa-adreno receptores.
FI954228A (fi) Infuusiolaite hoitoaineen jaksottaista tai jatkuvaa antamista varten
FI954767A (fi) Lipofiilisiä lääkeaineita sisältävä farmaseuttinen koostumus
DK0799028T3 (da) Formulering med styret afgift til tungt opløselige basiske lægemidler
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
ID29994A (id) Komposisi farmasi untuk melawan ccr5 terdiri dari turunan anilida
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
CO5130022A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
AU2084801A (en) Antiviral medication
BR9610983A (pt) Formas estáveis de administração farmacêuticas contendo paratormônio
PT1017392E (pt) Formulacao de medicamento com libertacao controlada do principio activo
NL193820B (nl) Vaste farmaceutische doseringsvorm voor orale toediening van Ibuprofen.
AU7291996A (en) Transdermal therapeutic system (tts) for the administration of drugs for treatment of drug dependency or drug addiction
HUP9901260A3 (en) Optically active phenylpyrimidine derivative as analgesic agent, process for producing it, pharmaceutical composition containing it and its intermediate
HUP0201405A2 (en) Pharmaceutical composition for therapeutic use of melatonin
PT1151746E (pt) Microcapsulas para libertacao sustentada de medicamentos
PL325242A1 (en) Method of obtaining solid drug administration forms for very low dosage drugs
LT99148A (en) Drug delivery devices and pharmaceutical composition for treatment wasting syndromes
IL115861A0 (en) Pharmaceutical formulation for controlled release of melatonin
SI0859595T1 (en) Therapeutic preparation for the transdermal administration of active substances
TH35426A (th) สารผสม
PL301249A1 (en) Application of iphosphamide as an anticarcinogenic drug

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 700285

Country of ref document: ES